Antitrust case filed against Dr Reddys Labs in the US over maintaining a shared monopoly in the sale of brand and generic Revlimid through their respective settlements of patent litigation with other pharmaceutical companies.
Dr Reddys Lab along with Celgene, Bristol Myers Squibb and several generic pharmaceutical companies, were named as defendants in a complaint filed on November 18, 2022, in the District of New Jersey, USA.
The complaint alleges that the challenged agreements improperly delayed generic entry entirely until 2022 and then improperly limited generic competition through 2026. The complaint seeks damages for purported overpayments and equitable relief.
Dr. Reddy’s Lab said it maintains that the allegations against it lack merit and will vigorously defend the litigation.
Generic drugmaker Dr Reddy's Labs reported a 12.2% rise in second-quarter profit which was gained by the launch of the generic version of Lenalidomide capsules in the U.S. market. It is the generic version of Bristol Myers Squibb's cancer drug Revlimid.
